{"id":4594,"date":"2013-02-06T13:22:59","date_gmt":"2013-02-06T11:22:59","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/?p=4594"},"modified":"2013-03-01T20:40:06","modified_gmt":"2013-03-01T18:40:06","slug":"chronic-granulomatous-disease-genethon-receives-approval-from-the-uk-medicine-regulatory-agency-to-start-a-new-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.institut-biotherapies.fr\/en\/2013\/02\/06\/chronic-granulomatous-disease-genethon-receives-approval-from-the-uk-medicine-regulatory-agency-to-start-a-new-clinical-trial\/","title":{"rendered":"Chronic granulomatous disease : Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial"},"content":{"rendered":"<p>On January 10th, the British Medicine and Healthcare Regulatory Agency (MHRA)\u00a0approved Genethon\u2019s Phase I \/ II gene therapy clinical trial application in X-linked\u00a0chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in\u00a0London. Genethon is also seeking approval for this multicenter trial in Germany,\u00a0Switzerland and France. In total the trial will include 20 patients (5 per site) to be\u00a0treated and followed up for 2 years. Genethon also obtained Orphan Drug\u00a0designation for this treatment from the European Medicines Agency (EMA).<\/p>\n<p><a title=\"Chronic granulomatous disease : Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial\" href=\"https:\/\/www.institut-biotherapies.fr\/wp-content\/uploads\/2013\/02\/insitut_biotherapies_granulomatose_genethon_ENG.pdf\">Read the press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On January 10th, the British Medicine and Healthcare Regulatory Agency (MHRA)\u00a0approved Genethon\u2019s Phase I \/ II gene therapy clinical trial application in X-linked\u00a0chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in\u00a0London. Genethon is also seeking approval for this multicenter trial in Germany,\u00a0Switzerland and France. In total the trial will include 20 patients &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/2013\/02\/06\/chronic-granulomatous-disease-genethon-receives-approval-from-the-uk-medicine-regulatory-agency-to-start-a-new-clinical-trial\/\">[Read more]<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-4594","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/4594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=4594"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/4594\/revisions"}],"predecessor-version":[{"id":4722,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/4594\/revisions\/4722"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=4594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/categories?post=4594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/tags?post=4594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}